1. Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1). (October 2022) Authors: Besse, B.; Springfeld, C.; Baik, C.; Hervieu, A.; Solomon, B.; Moreno, V.; Bazhenova, L.; Goto, K.; Kim, Y.C.; Lu, S.; Sun, M.; Trone, D.; Thamake, S.; Cho, B.C.; de Langen, A.; Popat, S.; Wolf, J.; Moro-Sibilot, D.; Fang, J.; Drilon, A. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗